Drugs / TTX-381
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05791864 | May 2023 → Jul 2026 overdue | neuronal ceroid lipofuscinosis 2 | Tern Therapeutics, LLC | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTX-381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05791864 ↗ |